Sera Prognostics, Inc. income statement SERA

Annual Quarterly

In fiscal 2025, which ended Dec 31, 2025, Sera Prognostics, Inc. reported revenue of $81,000, up 5.2% from the year before. It recorded a net loss of $31.9 million. The operating loss came to $36.5 million, an operating margin of -45066.7%. Diluted earnings per share were -$0.67. Over the twelve months ended Sep 30, 2026, revenue was $96,000 and the net loss was $33.5 million. Across the 5 fiscal years shown, revenue shrank from $82,000 in fiscal 2021 to $81,000 in fiscal 2025, about 0.3% a year.

USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.

FY 2026
Sep 30, 2026
FY 2025
Dec 31, 2025
FY 2024
Dec 31, 2024
FY 2023
Dec 31, 2023
FY 2022
Dec 31, 2022
FY 2021
Dec 31, 2021
Revenue
0
+1.1%
0
+5.2%
0
-74.8%
0
+14.2%
0
+226.8%
0
Cost of revenue
—
0
+100.0%
0
—
—
—
Gross profit
—
-0
-1560.0%
-0
—
—
—
Research and development
12
-4.8%
13
-10.6%
15
-3.3%
15
+6.9%
14
+29.3%
11
Selling, general and administrative
25
+3.5%
23
+6.2%
22
-11.3%
25
-21.6%
31
+28.9%
24
Operating expenses
—
36
-0.6%
37
—
—
—
Operating income
-37
-0.6%
-37
+0.4%
-37
+8.0%
-40
+12.8%
-46
-29.0%
-35
Interest expense
0
-57.1%
0
-67.9%
0
—
—
—
Other income (expense)
4
-14.3%
5
+21.8%
4
+3.6%
4
+138.0%
2
+34.9%
1
Pretax income
—
-32
—
—
—
—
Income tax
—
0
0
0
0
0
Net income
-33
-2.6%
-32
+2.9%
-33
+9.2%
-36
+18.0%
-44
-26.2%
-35
Basic EPS
-0.66
+11.2%
-0.67
+32.3%
-0.99
+14.7%
-1.16
+18.9%
-1.43
+38.6%
-2.33
Diluted EPS
-0.66
+11.2%
-0.67
+32.3%
-0.99
+14.7%
-1.16
+18.9%
-1.43
+38.6%
-2.33
Weighted average shares, basic
50
+15.5%
48
+43.7%
33
+6.3%
31
+0.8%
31
+106.2%
15
Weighted average shares, diluted
50
+15.5%
48
+43.7%
33
+6.3%
31
+0.8%
31
+106.2%
15
Other measures
Depreciation and amortization
1
-9.6%
1
+12.8%
1
-7.4%
1
+19.0%
1
+14.7%
1
EBITDA
-36
-0.9%
-36
+0.7%
-36
+8.0%
-39
+13.3%
-45
-29.2%
-35
Interest coverage
-6,200.83x
-4,056.00x
-1,308.39x
—
—
—
Margins
Gross margin
—
-102.47%
-6.49%
—
—
—
Operating margin
-38,755.21%
-45,066.67%
-47,577.92%
-13,013.40%
-17,034.33%
-43,164.63%
Pretax margin
—
-39,417.28%
—
—
—
—
Profit margin
-34,866.67%
-39,417.28%
-42,724.68%
-11,843.79%
-16,487.31%
-42,693.90%
EBITDA margin
-37,901.04%
-43,906.17%
-46,496.10%
-12,719.28%
-16,752.24%
-42,360.98%
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. The first column is the trailing twelve months through the latest quarter. More on our methodology.

New to this? Read How to Read an Income Statement, With a Real Example.

Company profile

Industry
Services-Medical Laboratories (SIC 8071)
Listed as
SERA (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Salt Lake City, UT
SEC filer status
Non-accelerated filer, Smaller reporting company, Emerging growth company
SEC CIK
1534969
Former names
SERA PROGNOSTICS, INC. (until Nov 4, 2026)

Other Services-Medical Laboratories companies

All 29 Services-Medical Laboratories companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.